Global Neural Stem Cells Market - 2024-2031

Overview

The global neural stem cells market reached US$ 431.36 million in 2023 and is expected to reach US$ 948.24 million by 2031, growing at a CAGR of 10.4% during the forecast period 2024-2031.

Neural stem cells are a specialized type of stem cell capable of self-renewal, proliferation and differentiation into the main types of cells found in the nervous system. These include neurons (nerve cells responsible for transmitting signals), astrocytes (supportive glial cells that maintain homeostasis and provide metabolic support) and oligodendrocytes (glial cells that produce myelin to insulate axons). Neural stem cells play a critical role in brain development, maintenance and repair of the central nervous system.

The neural stem cells market is experiencing robust growth, driven by advancements in regenerative medicine, increased investments in stem cell research and rising applications for treating neurological disorders. Neural stem cells are pivotal in research and clinical trials aimed at treating brain injuries, neurodegenerative diseases like Parkinson's and Alzheimer's and spinal cord injuries. For instance, the NIH study presents the list of cellular therapies for 7 neurodegenerative diseases including 33 trials that utilized neural stem progenitors and 8 that utilized differentiated neural cells, discussing the outcomes and challenges. Finally, trials were measured against standardized disease rating scales with long-term outcomes measured to establish the effectiveness of the treatment.

Market Dynamics: Drivers & Restraints

Rising prevalence of neurological disorders

The rising prevalence of neurological disorders is significantly driving the growth of the neural stem cells market and are expected to drive the market over the forecast period. With an aging population and an increasing number of individuals suffering from neurodegenerative diseases, such as Alzheimer's, Parkinson's and multiple sclerosis, the demand for innovative treatment solutions, like those based on neural stem cells, is growing.

As the global population ages, the incidence of age-related neurological disorders is rising. For instance, according to the Alzheimer's Association, nearly 7 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. This has spurred research into regenerative therapies, including neural stem cells based treatments that aim to repair or regenerate damaged brain tissue.

Parkinson's disease is also on the rise, a 2022 Parkinson's Foundation-backed study reveals that nearly 90,000 people are diagnosed with Parkinson's disease every year in the U.S. This represents a steep 50% increase from the previously estimated rate of 60,000 diagnoses annually. The need for effective treatments to slow disease progression or restore lost motor function is driving the market for neural stem cells, which are being studied for their ability to replace degenerated neurons.

High cost associated with neural stem cell products

The high cost associated with neural stem cell products is significantly hampering the growth of the neural stem cells market in several ways. These costs are driven by a combination of factors, including complex manufacturing processes, regulatory hurdles and the need for specialized infrastructure and expertise.

The process of isolating, culturing and expanding neural stem cells is complex and requires high levels of precision. Producing high-quality neural stem cells involves expensive bioreactors, specific growth factors and strict sterile conditions. The need for sophisticated equipment, such as automated stem cell culturing systems, increases costs. For instance, iXCells Biotechnologies' human neural stem cells (iPSC-derived, ALS) cost $1,078.00 and STEMCELL Technologies' human IPSC-derived neural progenitor cells cost $995.00.

Segment Analysis

The global neural stem cells market is segmented based on type, application, end-user and region.

Application:

The Parkinson's disease segment is expected to dominate the global neural stem cells market share

The Parkinson's disease segment holds a major portion of the neural stem cells market share and is expected to continue to hold a significant portion of the market share over the forecast period due to the high unmet medical need for effective treatments and the promising potential of neural stem cells to address this challenge.

The National Institute of Health has estimated that the number of people with PD over the age of 50 years is expected to reach around 9 million by 2030, a doubling since 2005, rising to over 12 million by 2040. Parkinson's disease, a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain, affects millions of people globally. The demand for innovative therapies, particularly stem cell-based treatments, has driven the substantial focus on Parkinson's disease within the neural stem cells market.

Current treatments for Parkinson's disease, such as levodopa and dopamine agonists, mainly focus on alleviating symptoms rather than addressing the underlying cause of the disease. These therapies become less effective over time and long-term use can cause serious side effects, such as dyskinesia. The limitations of current treatments have created a significant demand for disease-modifying therapies that could slow, halt, or reverse the damage to neurons. Neural stem cells offer a promising avenue to regenerate lost dopamine-producing neurons, making them highly sought after for PD treatment

North America is expected to hold a significant position in the global neural stem cells market

North America region is expected to hold the largest share in the global neural stem cells market over the forecast period. North America, particularly the United States has long been a global leader in stem cell research. Major academic institutions such as Harvard University, Neural Stem Cell Institute, Stanford University and Johns Hopkins University are at the forefront of stem cell and neuroscience research, including the development of neural stem cell therapies. These institutions advance neural stem cell research.

For instance, the Neural Stem Cell Institute (NSCI) is dedicated to developing regenerative stem cell therapies for diseases of the central nervous system (CNS). The institute's scientists are developing new antibody therapies to remove aggregated proteins due to tauopathies like Alzheimer's Disease, FTD, PSP and CTE, Parkinson's Disease and Huntington's Disease.

The presence of leading biotech companies, such as StemCells Inc., Aspen Neuroscience, Inc., Neuralstem and Mesoblast, contributes to innovation and the translation of research into clinical applications. These companies are working on neural stem cell-based therapies for various neurological conditions, including Parkinson's disease and spinal cord injuries.

For instance, in April 2024, Aspen Neuroscience, Inc. said that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open-label clinical trial to assess the safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe Parkinson's disease (PD).

Asia Pacific is growing at the fastest pace in the neural stem cells market

The Asia Pacific region is experiencing the fastest growth in the neural stem cells market. Countries like China and India are facing growing healthcare challenges due to aging populations and higher rates of chronic diseases, driving the need for innovative treatments like neural stem cells to manage or cure these conditions.

Many Asia Pacific countries are rapidly advancing their stem cell research infrastructure, with China, Japan and South Korea emerging as key hubs for stem cell research and development. For instance, China has become one of the top countries for stem cell research and clinical trials, with the Chinese Stem Cell Society actively fostering the growth of regenerative medicine. The Chinese government has committed significant funding to stem cell research, providing opportunities for breakthroughs in neural stem cell applications.

Additionally, in Japan, the government has introduced policies to accelerate regenerative medicine. Japan's Regenerative Medicine Promotion Law, passed in 2014, created a faster pathway for the clinical use of stem cell-based therapies, making it one of the most progressive markets in the Asia-Pacific region for stem cell innovations.

Competitive Landscape

The major global players in the neural stem cells market include Athersys, Inc., Thermo Fisher Scientific Inc., STEMCELL Technologies, Merck KGaA, Axol Bioscience Ltd., iXCells Biotechnologies, ALSTEM, Bio-Rad Laboratories, Inc., Alomone Labs, Lifeline Cell Technology and among others.

Why Purchase the Report?

• To visualize the global neural stem cells market segmentation based on type, application, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the neural stem cells market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global neural stem cells market report would provide approximately 70 tables, 78 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies